Evidence map›Paper›PMID 26157289›Full record

ArticleIndian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology

Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: A tertiary care center experience.

Rashmi Patnayak, Amitabh Jena, Nandyala Rukmangadha, Amit Kumar Chowhan, K Sambasivaiah, Bobbit Venkatesh Phaneendra, Mandyam Kumaraswamy Reddy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Improving accuracy of breast cancer biomarker testing in India.The Indian journal of medical research · 2017
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rashmi PatnayakDepartment of Pathology, Sri Venkateswar Institute of Medical Sciences, Tirupati, Andhra Pradesh, India.
Amitabh JenaDepartment of Surgical Oncology, Sri Venkateswar Institute of Medical Sciences, Tirupati, Andhra Pradesh, India.
Nandyala RukmangadhaDepartment of Pathology, Sri Venkateswar Institute of Medical Sciences, Tirupati, Andhra Pradesh, India.
Amit Kumar ChowhanDepartment of Pathology, Sri Venkateswar Institute of Medical Sciences, Tirupati, Andhra Pradesh, India.
K SambasivaiahDepartment of Medical Oncology, Sri Venkateswar Institute of Medical Sciences, Tirupati, Andhra Pradesh, India.
Bobbit Venkatesh PhaneendraDepartment of Pathology, Sri Venkateswar Institute of Medical Sciences, Tirupati, Andhra Pradesh, India.
Mandyam Kumaraswamy ReddyDepartment of Pathology, Sri Venkateswar Institute of Medical Sciences, Tirupati, Andhra Pradesh, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledBreast cancer, in India, is the second commonest cancer in females. Receptor status with ER/PR/Her 2 is now routinely done in patients with invasive carcinoma. The tumour suppressor gene, p53, is also present in most breast cancers. Proteins produced by a mutated p53 gene, accumulate in the nucleus of tumour cells and are detected by immunohistochemistry (IHC). We have undertaken this study with the aim to evaluate the ER, PR, HER-2 and p53 expressions in invasive breast carcinomas by IHC and to compare the HER-2 expression with various clinicopathological parameters. MATERIALS AND

methodsIn this retrospective single institutional study from January 2001 to December 2010, 389 cases of histopathologically diagnosed infiltrating carcinoma of breast were evaluated taking into account various parameters like age, tumour size, grade, lymph node involvement, ER and PR. HER-2 and p53 was done in 352 cases.

resultsThe age range was 23-90 years with a mean of 50.7 years. Majority of tumours were T2 (79.6%) and Grade II (60.9%). Our data showed overall 47.6% ER, 48.8% PR, 29.6% HER-2 and 69.2% p53 positivity. There was no significant correlation between HER-2 and age, tumour size, lymph node status, ER, and PR. There was significant correlation between HER-2 and tumour grade (P = 0.031), p53 (P < 0.001). There was no inverse correlation between HER-2 and combined ER, PR status. Triple-negative breast cancers which constituted 22.7% of our cases did not reveal any correlation with various parameters.

conclusionIn our study, ER status was low, and incidence of p53 was high. These findings suggest that many of the tumours in Indian females may be of an aggressive type, and novel treatment approaches may be tried. We conclude that the assessment of all four markers is desirable.

Indexed as

Breast cancerestrogen receptorhuman epidermal growth factor receptor-2immunohistochemistryp53progesterone receptor

Identifiers

PMID26157289
PMCPMC4477374

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.